Wannarat Pongpirul1, Wiwat Chancharoenthana1, Krit Pongpirul2,3, Asada Leelahavanichkul4, Wipawee Kittikowit5, Kamonwan Jutivorakool6, Bunthoon Nonthasoot7, Yingyos Avihingsanon1, Somchai Eiam-Ong1, Kearkiat Praditpornsilpa1, Natavudh Townamchai1. 1. Division of Nephrology, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. 2. Department of Preventive and Social Medicine, Chulalongkorn University, Bangkok, Thailand. 3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 4. Division of Immunology, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand. 5. Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 6. Division of Infectious Disease, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. 7. Department of Surgery, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Abstract
AIM: Donor-specific antibody (DSA) is a widely-used biomarker for antibody-mediated rejection (ABMR) but correctly indicates only 30-40% of patients with ABMR. Additional biomarkers of ABMR in kidney transplant recipients are needed. METHODS: All 68 kidney transplanted-recipients enrolled in this study were negative for graft rejection as determined by surveillance-biopsy ELISA at day 7 post-transplantation. Allograft biopsy was then performed at 6 months post-transplantation for subclinical-ABMR detection. Recipients were stratified by pre-transplant DSA and BAFF at day 7 into four groups. RESULTS: During the study period, 13.2% of the recipients demonstrated subclinical-ABMR at 6 months, without patient with clinical ABMR presentations. Overall mean BAFF at day 7 was 393 pg/mL (95% CI = 316-471 pg/mL). The optimal cut-off value for low vs. high BAFF level was 573 pg/mL, with sensitivity and specificity at 77.8% and 88.1%, respectively. Fifty percent of recipients with high BAFF at day 7 (14 patients) and only 3.7% of patients with low BAFF demonstrated ABMR (P < 0.05). Indeed, ABMR was more common in patients high BAFF level (hazard ratio = 7.30; 95% CI = 3.77-14.15). The prevalence of ABMR among negative pre-transplant DSA/low BAFF, positive DSA/low BAFF, negative DSA/high BAFF, and positive DSA/ high BAFF recipients were 4.4, 0, 37.5 and 66.7%, respectively (P < 0.05). CONCLUSIONS: Post-transplant ABMR can be predicted by perioperative serum BAFF level. Together with DSA testing, BAFF provides additional predictive value for ABMR.
AIM: Donor-specific antibody (DSA) is a widely-used biomarker for antibody-mediated rejection (ABMR) but correctly indicates only 30-40% of patients with ABMR. Additional biomarkers of ABMR in kidney transplant recipients are needed. METHODS: All 68 kidney transplanted-recipients enrolled in this study were negative for graft rejection as determined by surveillance-biopsy ELISA at day 7 post-transplantation. Allograft biopsy was then performed at 6 months post-transplantation for subclinical-ABMR detection. Recipients were stratified by pre-transplant DSA and BAFF at day 7 into four groups. RESULTS: During the study period, 13.2% of the recipients demonstrated subclinical-ABMR at 6 months, without patient with clinical ABMR presentations. Overall mean BAFF at day 7 was 393 pg/mL (95% CI = 316-471 pg/mL). The optimal cut-off value for low vs. high BAFF level was 573 pg/mL, with sensitivity and specificity at 77.8% and 88.1%, respectively. Fifty percent of recipients with high BAFF at day 7 (14 patients) and only 3.7% of patients with low BAFF demonstrated ABMR (P < 0.05). Indeed, ABMR was more common in patients high BAFF level (hazard ratio = 7.30; 95% CI = 3.77-14.15). The prevalence of ABMR among negative pre-transplant DSA/low BAFF, positive DSA/low BAFF, negative DSA/high BAFF, and positive DSA/ high BAFF recipients were 4.4, 0, 37.5 and 66.7%, respectively (P < 0.05). CONCLUSIONS: Post-transplant ABMR can be predicted by perioperative serum BAFF level. Together with DSA testing, BAFF provides additional predictive value for ABMR.
Authors: Isabel Legaz; Manuel Muro; Rafael Alfaro; Santiago Llorente; Pedro Martinez; Víctor Jimenez-Coll; Helios Martínez-Banaclocha; José Antonio Galián; Carmen Botella; María Rosa Moya-Quiles; Jesús de la Peña-Moral; Alfredo Minguela Journal: Arch Immunol Ther Exp (Warsz) Date: 2022-09-22 Impact factor: 3.831
Authors: Juan Irure-Ventura; David San Segundo; Emilio Rodrigo; David Merino; Lara Belmar-Vega; Juan Carlos Ruiz San Millán; Rosalía Valero; Adalberto Benito; Marcos López-Hoyos Journal: Int J Mol Sci Date: 2020-01-25 Impact factor: 5.923
Authors: Anthony Sabulski; Kasiani C Myers; Jack J Bleesing; Alexandra Duell; Adam Lane; Ashley Teusink-Cross; Stella M Davies; Sonata Jodele Journal: Blood Adv Date: 2021-11-23
Authors: Yuta Asano; Joe Daccache; Dharmendra Jain; Kichul Ko; Andrew Kinloch; Margaret Veselits; Donald Wolfgeher; Anthony Chang; Michelle Josephson; Patrick Cunningham; Anat Tambur; Aly A Khan; Shiv Pillai; Anita S Chong; Marcus R Clark Journal: Nat Commun Date: 2021-07-16 Impact factor: 17.694